CD19 and myeloid sarcoma: According to the type of CD19+ B cells, CD4+ T cells, pDCs, and PBMC, a total of 139 pathways were enriched at P < 0.05 for DEGs in MS patients without treatment (Supplementary Table S4), and a total of 112 pathways were enriched at P < 0.05 for DEGs in MS patients before and after Fingolimod or IFN-β application (Supplementary Table S5).